Herben may assist with managing symptoms related to physical discomfort and inflammatory or irritative states. The medication contains Niflumic acid, which belongs to a class of drugs known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), commonly used for managing symptoms related to inflammatory or irritative states. This therapeutic domain is commonly used to help with managing symptoms related to physical discomfort and inflammatory or irritative states associated with conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, osteoarthritis, dysmenorrhoea, and postoperative discomfort.

This class of medicine is applied in addressing symptoms related to inflammatory or irritative states such as those found in arthropathies. Herben may assist with managing symptoms related to systemic imbalance, such as fever. Applied across domains where additional symptomatic support is needed, this medication supports patients during difficult episodes by easing distress.

Quick Fact: May assist with managing symptoms related to physical discomfort.

In situations where patients experience symptoms related to inflammatory or irritative states, Herben may assist with managing symptoms related to physical discomfort, such as swelling and joint stiffness. This provides supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Australian Therapeutic Goods Administration (TGA) review of NSAID safety

Eligibility Map: Who Can and Cannot Use Herben — Official Regulatory Information

This section details the officially documented patient population for Herben, based strictly on government regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

---

Populations Excluded from Use

Classification	Regulatory Status
Absolute Contraindication	Patients with known hypersensitivity to the active substance or any excipients must not use Herben.
Age-Based Contraindication	Use is contraindicated in children under a specific young age (e.g., typically under 2 years) due to established safety risks.
Physiological State	Use during pregnancy and lactation is generally not recommended or contraindicated due to insufficient human data or documented risks.

---

Populations with Restricted or Conditional Use

Classification	Regulatory Status
Organ Impairment	Patients with severe hepatic or renal impairment are eligible only under restricted conditions, often requiring mandatory dose adjustments specified in the labeling.
Pediatric Status	Safety and efficacy are not yet established for the paediatric population (e.g., ages 2 to <18 years), meaning use is generally not recommended in this age group.
Older Adults	While often no initial dose adjustment is required solely based on age, use in patients aged 75 years and older may have limited data, requiring caution.

The regulatory profile clearly defines who cannot use the drug through absolute contraindications and formally limits eligibility for special populations—such as those with significant organ dysfunction or those who are pregnant—by deeming use either restricted or not recommended.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The regulatory profile for Herben (Diltiazem) is significantly shaped by its classification as a moderate inhibitor of the CYP3A4 enzyme system and the P-glycoprotein (P-gp) transporter. This pharmacological action is the basis for numerous pharmacokinetic interactions because it limits the body's ability to clear co-administered drugs that are substrates of these pathways.

Officially documented interactions include an increased systemic exposure and plasma concentration of drugs such as Cyclosporine, certain Statins (e.g., Simvastatin), Carbamazepine, and certain Benzodiazepines (e.g., Triazolam). Conversely, co-administration with strong CYP3A4 Inducers such as Rifampicin is documented to reduce Diltiazem's systemic levels.

Classification	Examples of Interacting Substances
Formal Contraindications	Ivabradine, Intravenous Beta-Blockers, Colchicine (in renal/hepatic impairment)
Pharmacodynamic Risk	Oral Beta-Blockers, other Anti-hypertensives, Antiarrhythmics

Pharmacodynamic interactions with other cardiovascular medicines, including Oral Beta-Blockers and Antiarrhythmic Agents, may lead to additive effects on heart rate and conduction. Furthermore, the label notes that the consumption of alcohol with extended-release formulations may result in an accelerated release of the active ingredient, and Grapefruit Juice may increase Diltiazem exposure.

How Herben Works

Herben’s mechanism of action is defined by its role as a specific inhibitor of the L-type Voltage-Gated Calcium Channels ( Ca v1.2) found throughout the cardiovascular system. By preventing the influx of calcium ions ( Ca^2+) into target cells, the drug simultaneously influences cardiac electrical activity, heart muscle contraction, and the tone of blood vessels.

---

Influencing the Heart's Electrical Conduction

The drug’s action targets the electrical pacemaker and conduction system, specifically the Sinoatrial (SA) and Atrioventricular (AV) nodes. The blockade of Ca^2+ channels in these tissues decreases the rate of electrical impulse generation and transmission, resulting in a reduction of the heart rate and prolonged conduction time. This effect is amplified during high rates of depolarization (use-dependence).

---

Reducing Vascular and Myocardial Contraction

This domain focuses on the drug's effect on muscle tissues where Ca^2+ is essential for contraction: the coronary and systemic arteries, and the myocardium. Reduced calcium availability promotes the relaxation and widening of the arteries (vasodilation) and concurrently lessens the force of the heart muscle’s contraction, thereby reducing the overall energy demand and mechanical burden on the myocardium.

Herben (Diltiazem) is administered via two main routes: orally for long-term chronic treatment, and intravenously (IV) for short-term acute clinical management. The available forms dictate the required dosing schedule. Extended-release (ER) products are generally utilized for once-daily administration, maintaining a typical maintenance dose between 180 mg and 420 mg daily for chronic conditions. Immediate-release tablets, conversely, require multiple divided doses per day (e.g., three to four times daily) to maintain consistent therapeutic levels.

Administration requires adherence to form-specific constraints. Extended-release forms are designed to be swallowed whole and are not to be chewed, crushed, or split, as such actions compromise the controlled release mechanism. Oral dose adjustments, known as titration, proceed slowly, with an interval of 7 to 14 days between changes to allow the full therapeutic effect to become evident.

The injectable form is used in acute care settings, starting with a weight-calculated IV bolus administered over 2 minutes, followed by a continuous infusion. The duration of this continuous IV infusion is typically restricted to a maximum of 24 hours. Furthermore, clinical protocols for older adults and patients with impaired hepatic or renal function involve starting with a lower initial dose, with subsequent increases performed with extra caution.

Research evidence / Overview of studies for Herben (Diltiazem)

Evidence for use in Atrial Arrhythmias and Rapid Heart Rate Control

Research has explored the use of Diltiazem for managing conditions characterized by episodic or acute changes in heart rhythm, such as Atrial Fibrillation or Paroxysmal Supraventricular Tachycardia (PSVT). These studies were primarily randomized controlled trials (RCTs) and systematic reviews that monitored outcomes related to physiological strain, specifically focusing on the speed and magnitude of ventricular heart rate change.

Studies conducted during periods of increased symptom activity examined how quickly the heart rate can be brought into a safer range. Findings documented measurements of ventricular heart rate change and the time required to achieve a controlled rate in minutes to a few hours following administration. The evidence base for short-term rate control is primarily derived from RCTs, but long-term effects are not fully established based on these trials.

---

Evidence for use in Chronic Stable Angina and Coronary Artery Spasm

Diltiazem was studied for use in managing chest discomfort related to effort (Chronic Stable Angina) and in cases where the discomfort is linked to artery spasm. The research includes placebo-controlled crossover trials which examined outcomes related to physical discomfort and daily functioning or activity level.

These trials focused on objective measures, such as the total time patients could exercise before experiencing discomfort and the frequency of patient-reported outcomes describing perceived discomfort. Crossover trials reported measurements where exercise duration was observed to be longer compared to the placebo period. Limited information for long-term outcomes exists from RCTs that tracked major events, such as heart attack or death, specifically in stable angina patients.

---

Evidence for use in Essential Hypertension (High Blood Pressure)

Diltiazem was evaluated in large-scale, long-term RCTs and observational cohorts tracking essential hypertension. These studies examined outcomes related to systemic or functional imbalance, specifically focusing on measurements of systolic and diastolic blood pressure change. Long-term studies monitored the incidence of major events like stroke and non-fatal heart attack over periods of several years. Research has described patterns related to blood pressure change, and while short-term changes are characterized, the evidence base does not consistently establish how Diltiazem compares to all other first-line antihypertensive classes regarding the prevention of long-term cardiovascular events.

---

What is Still Uncertain About Herben's Evidence

While short-term heart rate control appears to be well-characterized, long-term effects are not fully established for rhythm maintenance or cardiovascular event prevention, especially when compared to all contemporary alternatives. Research also highlights that Diltiazem's evaluation against placebo focused on the incidence of recurrent reinfarction and observed no statistically distinct difference in overall mortality during the study period for that specific indication. Overall, comparative evidence is lacking in some areas against newer medications, and sample sizes were modest in some of the older trials, meaning the findings describe group patterns but do not provide individual predictions.

Key Studies & References

1. Diltiazem - StatPearls - NCBI Bookshelf (General Evidence Monograph)
2. Dilitiazem in Comparison with metoprolol in stable angina pectoris

The storage and disposal requirements for Herben (Diltiazem Hydrochloride) are determined by the specific formulation, as defined by regulatory labeling.

---

Storage Conditions

Dosage Form	Required Storage Condition
Oral (Tablets/Capsules)	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Protect from excessive humidity and light.
Injection Solution	Store under refrigeration at 2 C to 8 C (36 F to 46 F). Do Not Freeze.

---

Handling and Disposal

The medicine must be kept in a tightly closed, light-resistant container and stored out of the sight and reach of children. Any reconstituted or diluted injection solution is stable for 24 hours. Disposal of unused or expired product must be done in accordance with all local/national regulations for pharmaceutical waste, with strict instructions to not allow the product to enter sewers or waterways.